Abstract
GABA(B) receptors form the basis of a powerful and versatile inhibitory system in the mammalian brain. Presynaptic and postsynaptic actions of GABA, receptors have been described in various brain regions, including the hippocampus. We report here on a novel pharmacological agent, presumably a peptide, which inhibits synaptic transmission in the CA1 area of the rat hippocampus via GABA, receptors. The agent is a component of a nootropic drug, Cerebrolysin®, obtained from pig's brain extract. In contrast to other, presently known agonists, such as baclofen or GABA, Cerebrolysin® acts preferentially on presynaptic GABA, receptors and has no detectable postsynaptic inhibitory effects. Additional, postsynaptic depolarizing action of the drug resulting in increased excitability is pharmacologically distinct from the GABA, response and partially masked by the inhibition. The presynaptic GABA, agonist may add to clinical effects of Cerebrolysin® in treatment of brain injuries. Moreover, it promises to be a useful experimental agent in further studies of many possible functional roles of GABA, receptors.
Original language | English (US) |
---|---|
Pages (from-to) | 188-194 |
Number of pages | 7 |
Journal | Brain Research |
Volume | 737 |
Issue number | 1-2 |
DOIs | |
State | Published - Oct 21 1996 |
Externally published | Yes |
Keywords
- Brain slice
- CA1
- Cerebrolysin
- GABA(B)
- Hippocampus
- Prespnaptic
- Receptor
- Synaptic transmission
ASJC Scopus subject areas
- Neuroscience(all)
- Molecular Biology
- Clinical Neurology
- Developmental Biology